Akebia Therapeutics, Inc. (AKBA) stock analysis
Healthcare · Drug Manufacturers - Specialty & Generic
From the 10-K filed 2026-02-26
Business type: Asset play
How it makes money
It earns by selling specialized medications to dialysis providers who prescribe them to patients managing chronic kidney disease complications.
Revenue is generated from the sale of Vafseo and Auryxia to dialysis organizations. Success depends on the adoption of these products by medical teams and the securing of supply contracts with the large organizations that manage nearly all dialysis patient care in the U.S.
What protects it: the moat
It relies on regulatory exclusivity for its newer drug, though it faces rapid erosion of its older product's market position due to generic entry.
Management asserts its leadership in the kidney community as a competitive advantage. However, the loss of exclusivity for Auryxia demonstrates how easily established earnings can be disrupted by generic competitors, leaving the company's future protection heavily dependent on the clinical adoption of Vafseo.
What growth costs
Growth requires heavy ongoing investment in clinical trials and research to advance its pipeline of rare disease drug candidates.
The company must continually commit significant capital to research and development. Because it has not yet achieved consistent profitability, these costs are funded through historical cash reserves, licensing deals, and equity sales.
What could damage it
A failure to maintain favorable reimbursement contracts with major dialysis organizations would permanently destroy its ability to distribute and monetize its primary therapeutics.
Because the market for its products is highly concentrated among a small number of large dialysis providers, the loss of any major supply agreement or a shift in reimbursement protocols would cause a collapse in the realized value of its commercial assets.
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.